Molecular Imaging 2017

SPECTRO GLIO Newly Diagnosed Glioblastoma Prospective multicentric phase III trial Promoted by Institut Claudius Regaud– financed by French national cancer institute

220 patients – 9 institutions

MRI + spectro

Randomization

60 Gy + TMZ + 72 Gy/2,4 Gy IMRT SIB guided by MR spectroscopy

60 Gy + TMZ

MRI + spectro /2months

Global survival

MR spectroscopic imaging for dose-painting

21